Page last updated: 2024-12-04

bethanidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bethanidine: A guanidinium antihypertensive agent that acts by blocking adrenergic transmission. The precise mode of action is not clear. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2368
CHEMBL ID1201260
CHEBI ID37937
SCHEMBL ID34432
MeSH IDM0002444

Synonyms (41)

Synonym
2-benzyl-1,3-dimethylguanidine
guanidine, 2-benzyl-1,3-dimethyl-
1,2-dimethyl-3-(phenylmethyl)guanidine
guanidine, n,n'-dimethyl-n''-(phenylmethyl)-
betanidina [inn-spanish]
betanidinum [inn-latin]
betanidine [inn:ban]
guanidine, 1-benzyl-2,3-dimethyl-
1-benzyl-2,3-dimethylguanidine
betanidina
55-73-2
bethanidine
betanidine
CHEBI:37937 ,
betanidinum
n,n'-dimethyl-n''-(phenylmethyl)-guanidine
bethanidine sulfate (2:1) (usan)
guanidine, 1-benzyl-2,3-dimethyl-, sulfate (2:1)
sulfuric acid compound with n''-benzyl-n,n'-dimethylguanidine (1:1)
2-benzyl-1,3-dimethyl-guanidine
guanidine, n, n'-dimethyl-n''-(phenylmethyl)-, sulfate (2:1)
DB00217
L001022
FT-0693090
CHEMBL1201260
w8s3ym7auu ,
unii-w8s3ym7auu
AKOS006228716
gtpl7618
2,3-dimethyl-1-(phenylmethyl)guanidine
SCHEMBL34432
bethanidine [mi]
betanidine [inn]
betanidine [who-dd]
NIVZHWNOUVJHKV-UHFFFAOYSA-N
n-benzyl-n'-methyl-n''-[(e)-methyl]guanidine #
DTXSID7022677
(e)-3-benzyl-1,2-dimethylguanidine
Q794152
n''-benzyl-n,n'-dimethylguanidine
EN300-6961197

Research Excerpts

Overview

Bethanidine is a potent sympathetic blocking agent in man with properties intermediate between those of bretylium and guanethidine. Bethanidine sulfate has virtually identical antifibrillatory and inotropic actions on the heart.

ExcerptReferenceRelevance
"Bethanidine (BW467C60) is a newly presented strong adrenergic neuron blocking factor which has a hypotensive operation in man. "( Computational drug repurposing of bethanidine for SENP1 inhibition in cardiovascular diseases treatment.
Minuchehr, Z; Sabouni, F; Taghvaei, S, 2022
)
2.44
"Bethanidine is a potent sympathetic blocking agent in man with properties intermediate between those of bretylium and guanethidine."( THE EFFECTS OF BETHANIDINE ON THE PERIPHERAL CIRCULATION IN MAN.
FEWINGS, JD; HODGE, RL; SCROOP, GC; WHELAN, RF, 1964
)
1.32
"Bethanidine sulfate is a chemical and pharmacologic analog of bretylium tosylate that has virtually identical antifibrillatory and inotropic actions on the heart. "( Antiarrhythmic, antifibrillatory, and hemodynamic actions of bethanidine sulfate: an orally effective analog of bretylium for suppression of ventricular tachyarrhythmias.
Bacaner, MB; Benditt, DG, 1982
)
1.95
"Bethanidine sulfate is a closely related chemical analog of bretylium that has virtually identical pharmacologic and antifibrillatory actions on the ventricle. "( Suppression of ventricular fibrillation and positive inotropic action of bethanidine sulfate, a chemical analog of bretylium tosylate that is well absorbed orally.
Bacaner, MB; Hoey, MF; Macres, MG, 1982
)
1.94
"Bethanidine sulfate is a congener of bretylium tosylate, which has been reported to have antiarrhythmic and antifibrillatory effects. "( Electrophysiological effects of bethanidine sulfate on canine cardiac Purkinje fibers and ventricular muscle cells.
Dangman, KH; Miura, DS,
)
1.86

Effects

ExcerptReferenceRelevance
"Bethanidine has been administered intra-arterially and intravenously into normotensive subjects and its effects on the limb blood vessels, arterial blood pressure, vascular sensitivity to noradrenaline and the degree and time course of sympathetic nerve blockade have been studied. "( THE EFFECTS OF BETHANIDINE ON THE PERIPHERAL CIRCULATION IN MAN.
FEWINGS, JD; HODGE, RL; SCROOP, GC; WHELAN, RF, 1964
)
2.04

Toxicity

ExcerptReferenceRelevance
" Other reported effects are toxic confusional states and psychotic reactions."( Psychiatric side effects of antihypertensive drugs other than reserpine.
Fleminger, R; Paykel, ES; Watson, JP, 1982
)
0.26

Pharmacokinetics

ExcerptReferenceRelevance
" Therefore, pharmacokinetic modeling of urinary excretion data alone would lead to erroneous conclusions concerning the persistence of drug in the blood."( Time-dependent change in renal clearance of bethanidine in humans.
Chremos, AN; Gibaldi, M; Newman, JH; Proctor, JD; Shen, D, 1976
)
0.52

Bioavailability

Unlike bretylium, which is poorly absorbed from the gut and limited to parenteral use, oral bethanidine is absorbed rapidly.

ExcerptReferenceRelevance
"" Unlike bretylium, which is poorly absorbed from the gut and limited to parenteral use, oral bethanidine is absorbed rapidly."( Antiarrhythmic, antifibrillatory, and hemodynamic actions of bethanidine sulfate: an orally effective analog of bretylium for suppression of ventricular tachyarrhythmias.
Bacaner, MB; Benditt, DG, 1982
)
0.72
" Unlike bretylium, which is very poorly absorbed from the gut, bethanidine is rapidly and effectively absorbed after oral administration."( Suppression of ventricular fibrillation and positive inotropic action of bethanidine sulfate, a chemical analog of bretylium tosylate that is well absorbed orally.
Bacaner, MB; Hoey, MF; Macres, MG, 1982
)
0.74

Dosage Studied

During programmed ventricular stimulation after 59 trials of 20 to 30 mg/kg body weight of oral bethanidine, no ventricular tachyarrhythmias were inducible in 6 patients. The effects of sudden withdrawal from chronicBethanidine dosing were observed in six patients.

ExcerptRelevanceReference
" The first dose was given 1 h before rising, and the daily dosage was progressively increased."( Dihydroergotamine: an effective treatment for postural hypotension due to antihypertensive drugs (ganglion-blocking agents excepted).
Conté, JJ; Fournié, GJ; Maurette, MH, 1976
)
0.26
" The effects of sudden withdrawal from chronic bethanidine dosing were observed in six patients."( Bethanidine dose, plasma levels, and antihypertensive effects.
Corder, CN,
)
1.83
" Dose-response lines in response to the two agonists, expressed as percent maximal contraction, did not differ among the groups."( Muscarinic-receptor functioning in tracheas from normal and ovalbumin-sensitive guinea pigs.
Biggs, DF; Yang, ZJ, 1991
)
0.28
" Serious adverse reactions necessitate a change in antiarrhythmic therapy, as opposed to lowering drug dosage to an ineffective level."( Antiarrhythmic drug therapy. Recent advances and current status.
Somberg, J, 1985
)
0.27
" During programmed ventricular stimulation after 59 trials of 20 to 30 mg/kg body weight of oral bethanidine (acute dosing in 40 patients, and divided dosing over 24 hours in 19 patients), no ventricular tachyarrhythmias were inducible in 6 patients (11%), sustained ventricular tachycardia was converted to nonsustained ventricular tachycardia in 3 patients (5%), ventricular tachyarrhythmias remained inducible in 39 patients (70%) and spontaneous ventricular tachyarrhythmias occurred more frequently in 4 patients (7%)."( Bethanidine sulfate: efficacy in prevention of ventricular tachyarrhythmias during programmed stimulation. Report of a multicenter study of 56 patients.
Fisher, JD; Kim, SG; Matos, JA; Teichman, SL; Waspe, LE, 1985
)
1.93
" If side effects intervene that may cause continued therapy to be intolerable, changing the antiarrhythmic agent, as opposed to decreasing the dosage to an ineffective range, may be appropriate."( New directions in antiarrhythmic drug therapy.
Somberg, JC, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
adrenergic antagonistAn agent that binds to but does not activate adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
guanidinesAny organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (99)

TimeframeStudies, This Drug (%)All Drugs %
pre-199090 (90.91)18.7374
1990's6 (6.06)18.2507
2000's2 (2.02)29.6817
2010's0 (0.00)24.3611
2020's1 (1.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.34 (24.57)
Research Supply Index4.82 (2.92)
Research Growth Index3.98 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (13.89%)5.53%
Reviews9 (8.33%)6.00%
Case Studies2 (1.85%)4.05%
Observational0 (0.00%)0.25%
Other82 (75.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]